BlossomHill Therapeutics, Inc. (BLSM) — real insider trading activity disclosed to the SEC, tracked automatically as new Form 4 filings are reported. Most recent: GORDON CARL L disclosed a transaction on 2026-08-10 worth $10,000,000.
Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| Chen Bihua | Insider | 2026-08-10 | 1,599,993 | $0 |
| Chen Bihua | Insider | 2026-08-10 | 1,701,541 | $0 |
| Chen Bihua | Insider | 2026-08-10 | 312,500 | $5,000,000 |
| Schmid John P. | Insider | 2026-08-10 | 6,000 | $96,000 |
| Keyes Jason A | Chief Financial Officer | 2026-08-10 | 700 | $11,200 |
| Li Yishan | Executive Chairman | 2026-08-10 | 1,600,682 | $0 |
| Li Yishan | Executive Chairman | 2026-08-10 | 113,435 | $0 |
| Li Yishan | Executive Chairman | 2026-08-10 | 124,779 | $0 |
| Cui Jingrong Jean | President and CEO | 2026-08-10 | 1,600,682 | $0 |
| Cui Jingrong Jean | President and CEO | 2026-08-10 | 113,435 | $0 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
A fresh Form 4 filing shows Carl L. Gordon, a director of BlossomHill Therapeutics, Inc. (BLSM), purchased 625,000 shares of the company on the open market on August 10, 2026. The transaction, priced at $16.00 per share, totaled $10,000,000.00 — a purchase made with the insider’s own funds rather than acquired through options or other … Read more
A director of BlossomHill Therapeutics, Inc. (BLSM) put real money on the table this week. According to a Form 4 filing, OrbiMed Advisors LLC purchased 625,000 shares of BlossomHill on August 10, 2026, in an open-market transaction priced at $16.00 per share. The total outlay came to an even $10,000,000.00, funded directly by the insider … Read more